Trial Profile
Phase I Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Palbociclib (Primary)
- Indications Mantle-cell lymphoma
- Focus Adverse reactions
- 25 Jun 2019 Status changed from completed to discontinued.
- 10 Dec 2013 Final results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
- 09 Dec 2013 Status changed from recruiting to completed.